Phenotypes Associated with This Genotype

Genotype
MGI:4839782

• Allelic Composition: Ifngr1^tm1Agt/Ifngr1^tm1Agt; Tg(GZMB-Tax)#Lera/0
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

Increased osteolytic lesion formation and enhanced osteoclast activity in Ifngr1^tm1Agt/Ifngr1^tm1Agt Tg(GZMB-Tax)#Lera/0 mice

skeleton

abnormal osteoclast differentiation ( J:147601 )

• osteoclast formation from bone marrow derived macrophage is enhanced compared to in Tg(GZMB-Tax)#Lera mice

increased osteoclast cell number ( J:147601 )

• mice develop more peripheral soft tissue tumors by 6 months compared with Tg(GZMB-Tax)#Lera mice

• however, treatment with IFN-gamma inhibits tumor formation in vivo

abnormal osteoclast physiology ( J:147601 )

• mice exhibit an increase in tartrate-resistant acid phosphatase-expressing osteoclasts compared to in Tg(GZMB-Tax)#Lera mice

increased skeletal tumor incidence ( J:147601 )

• at 6 months, 89% of mice develop osteolytic skeletal tumors

• at 9 months, mice exhibit an increase in the number of osteolytic bone lesions compared with Tg(GZMB-Tax)#Lera mice

decreased bone mineral density ( J:147601 )

• mice exhibit decreased bone mineral density compared to in Tg(GZMB-Tax)#Lera mice

• however, IFN-gamma administration prevents

neoplasm

increased tumor incidence ( J:147601 )

• mice develop more peripheral soft tissue tumors by 6 months compared with Tg(GZMB-Tax)#Lera mice

• however, treatment with IFN-gamma inhibits tumor formation in vivo

increased skeletal tumor incidence ( J:147601 )

• at 6 months, 89% of mice develop osteolytic skeletal tumors

• at 9 months, mice exhibit an increase in the number of osteolytic bone lesions compared with Tg(GZMB-Tax)#Lera mice

homeostasis/metabolism

increased circulating calcium level ( J:147601 )

• mice exhibit increased serum calcium levels compared with wild-type mice and Tg(GZMB-Tax)#Lera mice

• however, IFN-gamma administration prevents hypercalcemia

immune system

abnormal osteoclast differentiation ( J:147601 )

• osteoclast formation from bone marrow derived macrophage is enhanced compared to in Tg(GZMB-Tax)#Lera mice

increased osteoclast cell number ( J:147601 )

• mice develop more peripheral soft tissue tumors by 6 months compared with Tg(GZMB-Tax)#Lera mice

• however, treatment with IFN-gamma inhibits tumor formation in vivo

abnormal osteoclast physiology ( J:147601 )

• mice exhibit an increase in tartrate-resistant acid phosphatase-expressing osteoclasts compared to in Tg(GZMB-Tax)#Lera mice

hematopoietic system

abnormal osteoclast differentiation ( J:147601 )

• osteoclast formation from bone marrow derived macrophage is enhanced compared to in Tg(GZMB-Tax)#Lera mice

increased osteoclast cell number ( J:147601 )

• mice develop more peripheral soft tissue tumors by 6 months compared with Tg(GZMB-Tax)#Lera mice

• however, treatment with IFN-gamma inhibits tumor formation in vivo

abnormal osteoclast physiology ( J:147601 )

• mice exhibit an increase in tartrate-resistant acid phosphatase-expressing osteoclasts compared to in Tg(GZMB-Tax)#Lera mice

cellular

abnormal osteoclast differentiation ( J:147601 )

• osteoclast formation from bone marrow derived macrophage is enhanced compared to in Tg(GZMB-Tax)#Lera mice